In 2019, researchers at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA realized that existing neuroelectronic therapies were failing patients - invasive, low-resolution, and unable to adapt to individual needs. They understood graphene, with its extraordinary biocompatibility and electrical properties, could enable a new generation of neural interfaces that could truly decode and modulate brain activity with unprecedented precision. So they founded INBRAIN Neuroelectronics to build the world's most intelligent, least invasive neural platform using graphene-based brain-computer interfaces.
Today, INBRAIN has successfully achieved the world's first human implant of a graphene-based cortical interface, marking a pivotal milestone in neurotechnology. Their end-to-end platform combines hardware, data analytics, and AI-powered algorithms to deliver real-time precision neurology - detecting specific biomarkers and triggering adaptive therapeutic responses personalized to each patient's condition. With FDA Breakthrough Device Designation for Parkinson's Disease and a team of over 70 people from 20 different countries, INBRAIN is pioneering therapies for neurological disorders including Parkinson's, epilepsy, and stroke, proving that graphene can safely revolutionize how we treat the human brain.